FeesSafety
Pluang+

Lisaftoclax gains Breakthrough Therapy Designation in China for first-line CLL/SLL treatment

Market News
21 Oct 2026, 02:30 WIB
GlobeNewsWire
View Source
Bullish
Lisaftoclax gains Breakthrough Therapy Designation in China for first-line CLL/SLL treatment

Ascentage Pharma's lisaftoclax, combined with acalabrutinib, received Breakthrough Therapy Designation from China's NMPA for treating treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). This designation accelerates development and review, reflecting the urgent need for improved therapies in CLL/SLL, a cancer affecting mainly older adults with rising incidence in China. Lisaftoclax is already approved in China for previously treated CLL/SLL patients and is undergoing global Phase III trials for first-line use. This advancement may lead to faster patient access to this novel treatment option.

Ascentage Pharma’s lisaftoclax breakthrough therapy designation provides context for health sector activity. For readers following Health stocks, here is Pluang's market snapshot as of Oct 21, 2026 05:01 WIB: Out of 150 priced US Health stocks, 129 rose and 21 fell today. Among notable movers, AMWL rose 7.46% to USD 13.25 with a typical hold time of 62 days, contrasting with DYN and ERAS, which gained 7.29% and 7.27% respectively but have much shorter typical hold times of 2 days and 100% buy order activity on DYN and ERAS.

More News

Ashland board approves $0.42 quarterly dividend payable December 15, 2026

Ashland board approves $0.42 quarterly dividend payable December 15, 2026

Ashland Inc.'s board of directors declared a quarterly cash dividend of $0.42 per share, payable on December 15, 2026, to shareholders of record as of December 1, 2026. This dividend reflects the company's ongoing commitment to returning value to sha...

Company Fundamentals
Bullish
25 minutes ago
AeroVironment wins $405M order for laser systems to boost Middle East counter-drone defense

AeroVironment wins $405M order for laser systems to boost Middle East counter-drone defense

AeroVironment secured a $405 million international order for its LOCUST X3 high-energy laser weapon systems, enhancing counter-drone defense capabilities in the Middle East amid rising regional security threats. Following the announcement, AeroVironm...

Market News
Bullish
1 hour ago
Vestas Q3 2026 earnings and revenue miss estimates, shares fall and guidance is cut

Vestas Q3 2026 earnings and revenue miss estimates, shares fall and guidance is cut

Vestas Wind Systems reported Q3 2026 earnings per share of $0.13 and revenue of $6.34 billion, both below analyst expectations. The company's profit was impacted by weak sales volume and a broken turbine blade. Following the earnings miss, Vestas' sh...

Company Fundamentals
Bearish
1 hour ago
Global beverage market to reach $2.78T by 2032, driven by nonalcoholic drinks and convenience trends.

Global beverage market to reach $2.78T by 2032, driven by nonalcoholic drinks and convenience trends.

The global beverage market is projected to grow from $2.03 trillion in 2026 to $2.78 trillion by 2032, at a CAGR of 5.35%. Growth is fueled by rising demand for nonalcoholic and functional beverages, convenience packaging, and premium products for sp...

Market News
Bullish
3 hours ago
Over 200 GLP-1 and incretin therapies in development are reshaping diabetes and obesity treatment landscapes.

Over 200 GLP-1 and incretin therapies in development are reshaping diabetes and obesity treatment landscapes.

DelveInsight's 2026 report reveals more than 200 GLP-1 receptor agonists and incretin-based therapies are in development by over 180 companies, targeting conditions like type 2 diabetes, obesity, and related metabolic disorders. Key players such as E...

Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App